Related Experiment Video
Updated: Jan 20, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
1Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA. aahmad@health.southalabama.edu.
Abstract:
Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and its continued importance is underlined by recent FDA approvals of its biosimilar and conjugated versions. Progression to an aggressive disease with acquisition of resistance to trastuzumab remains a major clinical concern. In addition to a number of cellular signaling pathways being investigated, focus in recent years has also shifted to epigenetic and non-coding RNA basis of acquired resistance against trastuzumab. This article provides a succinct discussion on the most recent advances in our understanding of such factors.
Insights
Trastuzumab is a key therapy for HER2-amplified breast cancer. Recent research explores epigenetic and non-coding RNA mechanisms driving acquired resistance to this vital treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Trastuzumab is a primary therapy for HER2-amplified breast cancer.
- Despite its efficacy, acquired resistance remains a significant clinical challenge.
- Recent FDA approvals highlight the ongoing importance of Trastuzumab and its variants.
Purpose of the Study:
- To discuss recent advances in understanding acquired resistance to Trastuzumab.
- To focus on epigenetic and non-coding RNA mechanisms contributing to treatment resistance.
Main Methods:
- Review of recent scientific literature.
- Analysis of emerging research on epigenetic modifications.
- Investigation of non-coding RNA's role in Trastuzumab resistance.
Main Results:
- Acquired resistance to Trastuzumab is a complex process.
- Epigenetic alterations play a crucial role in resistance development.
- Non-coding RNAs are increasingly recognized as key mediators of resistance.
Conclusions:
- Understanding epigenetic and non-coding RNA mechanisms is vital for overcoming Trastuzumab resistance.
- Future therapeutic strategies may target these epigenetic and non-coding RNA pathways.
- Continued research is needed to develop novel treatments for resistant HER2-positive breast cancer.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Electrical Current
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance

